A Phase 1, Multicenter, Open-Label Study of JCAR017, CD19-targeted Chimeric Antigen Receptor (CAR) T Cells, for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL).

Trial Profile

A Phase 1, Multicenter, Open-Label Study of JCAR017, CD19-targeted Chimeric Antigen Receptor (CAR) T Cells, for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL).

Recruiting
Phase of Trial: Phase I

Latest Information Update: 13 Dec 2017

At a glance

  • Drugs Lisocabtagene-maraleucel (Primary)
  • Indications Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Non-Hodgkin's lymphoma
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Acronyms TRANSCEND; TRANSCEND NHL 001
  • Sponsors Juno Therapeutics
  • Most Recent Events

    • 11 Dec 2017 Results presented in a Juno Therapeutics media release.
    • 09 Dec 2017 According to a Juno Therapeutics media release, data from this trial was presented at the, 59th American Society of Hematology (ASH) Annual Meeting.
    • 01 Nov 2017 Results published in the Juno Therapeutics Media Release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top